Neurobiological background of negative symptoms (Q30913824)

27 June 2017

1 reference

title

Neurobiological background of negative symptoms (English)

1 reference

27 June 2017

Armida Mucci

3

0 references

Silvana Galderisi

object named as

Silvana Galderisi

series ordinal

1

0 references

author name string

Eleonora Merlotti

series ordinal

2

1 reference

27 June 2017

publication date

24 March 2015

1 reference

European Archives of Psychiatry and Clinical Neuroscience

27 June 2017

published in

1 reference

27 June 2017

volume

265

1 reference

27 June 2017

issue

7

1 reference

27 June 2017

page(s)

543-558

1 reference

The NIMH-MATRICS consensus statement on negative symptoms

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Historical, psychopathological, neurological, and neuropsychological aspects of deficit schizophrenia: a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Deficit schizophrenia: an overview of clinical, biological and treatment aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

A separate disease within the syndrome of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Categorical and dimensional approaches to negative symptoms of schizophrenia: focus on long-term stability and functional outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Subdomains within the negative symptoms of schizophrenia: commentary

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

The structure of negative symptoms within schizophrenia: implications for assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Persistent negative symptoms in schizophrenia: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Cognitive correlates of the negative, disorganized, and psychotic symptom dimensions of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Cognitive markers of short-term clinical outcome in first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Identifying persistent negative symptoms in first episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

The brief negative symptom scale: psychometric properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Factor structure of the Brief Negative Symptom Scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

The factorial structure of the schedule for the deficit syndrome in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

A two-factor structure for the Schedule for the Deficit Syndrome in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Avolition and expressive deficits capture negative symptom phenomenology: Implications for DSM-5 and schizophrenia research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Ventricular enlargement in schizophrenia evaluated with computed tomographic scanning. Effects of gender, age, and stage of illness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Clinical correlates of postmortem brain changes in schizophrenia: decreased brain weight and length correlate with indices of early impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Ten year progressive ventricular enlargement in schizophrenia: an MRI morphometrical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Cognitive impairment in schizophrenia: Specific relations to ventricular size and negative symptomatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

The BPRS in assessing symptom correlates of cerebral ventricular enlargement in acute and chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. IV. Further evidence for regional and behavioral specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Speculation on the meaning of cerebral metabolic hypofrontality in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Negative symptoms in schizophrenia: neurobiological models and treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

The functional neuroanatomy of symptom dimensions in schizophrenia: a qualitative and quantitative review of a persistent question.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Structural abnormalities in the frontal system in schizophrenia. A magnetic resonance imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Magnetic resonance brain images in schizophrenic and normal subjects: influence of diagnosis and education

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

An evaluation of structural and functional prefrontal deficits in schizophrenia: MRI and neuropsychological measures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Volumetric analysis of frontal lobe regions in schizophrenia: relation to cognitive function and symptomatology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Prefrontal cortex, negative symptoms, and schizophrenia: an MRI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Cortical gray and white matter volume in unmedicated schizotypal and schizophrenia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

The relationship between symptom severity and regional cortical and grey matter volumes in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Morphology of the orbitofrontal cortex in first-episode schizophrenia: relationship with negative symptomatology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

A magnetic resonance imaging study of schizophrenia: brain structure and clinical symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

White matter alterations in schizophrenic patients with pronounced negative symptomatology and with positive family history for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Dissociable contributions of MRI volume reductions of superior temporal and fusiform gyri to symptoms and neuropsychology in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Corpus callosum shape and size in male patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Correlations between clinical symptoms, working memory functions and structural brain abnormalities in men with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Post-mortem study of chronic schizophrenic brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Postmortem Studies in Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

SPECT analysis of regional cerebral blood flow changes in patients with schizophrenia during the Wisconsin Card Sorting Test

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Single-photon emission computed tomography with 99mTc-exametazime in unmedicated schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Temporal lobe dysfunction and correlation of regional cerebral blood flow abnormalities with psychopathology in schizophrenia and major depression--a study with single photon emission computed tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Cerebral metabolic activity correlates of subsyndromes in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Psychopathological and SPECT findings in never‐treated schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Functional imaging of memory retrieval in deficit vs nondeficit schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Active and remitted schizophrenia: psychopathological and regional cerebral blood flow findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Negative symptoms and hypofrontality in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Limbic System Abnormalities Identified in Schizophrenia Using Positron Emission Tomography With Fluorodeoxyglucose and Neocortical Alterations With Deficit Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

A PET study of the pathophysiology of negative symptoms in schizophrenia. Positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Positive and negative symptoms and regional cerebral perfusion in antipsychotic-naive schizophrenic patients: a high-resolution SPECT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Clinical symptoms and regional cerebral blood flow in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Resting Cerebral Glucose Metabolism in First-Episode and Previously Treated Patients With Schizophrenia Relates to Clinical Features

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Improvement of brain reward abnormalities by antipsychotic monotherapy in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Dysfunction of ventral striatal reward prediction in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Reward feedback alterations in unmedicated schizophrenia patients: relevance for delusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Alterations of the brain reward system in antipsychotic naïve schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Abnormal responses to monetary outcomes in cortex, but not in the basal ganglia, in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Altered reward functions in patients on atypical antipsychotic medication in line with the revised dopamine hypothesis of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Neural correlates of reward processing in schizophrenia--relationship to apathy and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Ventral striatal activation during attribution of stimulus saliency and reward anticipation is correlated in unmedicated first episode schizophrenia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Deficit schizophrenia: Concept and validity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Emotion deficits in people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Clinical subtypes of schizophrenia: differences in brain and CSF volume

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Stereotaxy-based regional brain volumetry applied to segmented MRI: validation and results in deficit and nondeficit schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Patterns of structural MRI abnormalities in deficit and nondeficit schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Structural abnormalities in frontal, temporal, and limbic regions and interconnecting white matter tracts in schizophrenic patients with prominent negative symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Patterns of cranial, brain and sulcal CSF volumes in male and female deficit and nondeficit patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Structural abnormalities in deficit and nondeficit schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Dorsolateral prefrontal cortex volume in patients with deficit or nondeficit schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Alterations of mismatch negativity (MMN) in schizophrenia patients with auditory hallucinations experiencing acute exacerbation of illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Cerebral blood flow in schizophrenia: effects of memory processing on regional activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Magnetic resonance imaging in schizophrenia: relationship with clinical measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Gray-matter abnormalities in deficit schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Reduced anterior cingulate gray matter volume and thickness in subjects with deficit schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

White matter alterations in deficit schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Reduced left uncinate fasciculus fractional anisotropy in deficit schizophrenia but not in non‐deficit schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Neuroimaging evidence for the deficit subtype of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Abnormal patterns of regional cerebral blood flow in schizophrenia with primary negative symptoms during an effortful auditory recognition task

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Regional cerebral blood flow in deficit/nondeficit types of schizophrenia according to SDS criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

A Tc-99m HMPAO SPECT study of regional cerebral blood flow in drug-free schizophrenic patients with deficit and non-deficit syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Orbitofrontal cortex abnormality and deficit schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Persisting negative symptoms and information-processing deficits in schizophrenia: implications for subtyping

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Phasic and enduring negative symptoms in schizophrenia: biological markers and relationship to outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Lifelong course of positive and negative symptoms in chronically institutionalized patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Neurocognition and neuroimaging of persistent negative symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

The Structural Neural Substrates of Persistent Negative Symptoms in First-Episode of Non-Affective Psychosis: A Voxel-Based Morphometry Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Brain activity during emotionally negative pictures in schizophrenia with and without flat affect: an fMRI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Limbic activation associated with misidentification of fearful faces and flat affect in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Emotional face processing and flat affect in schizophrenia: functional and structural neural correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Anhedonia in schizophrenia: a review of assessment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

What aspects of emotional functioning are impaired in schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Goal representations and motivational drive in schizophrenia: the role of prefrontal-striatal interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

The "anhedonia paradox" in schizophrenia: insights from affective neuroscience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Schizophrenia in translation: dissecting motivation in schizophrenia and rodents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Long-lasting psychotomimetic consequences of repeated low-dose amphetamine exposure in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Increased baseline occupancy of D2 receptors by dopamine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Dopamine in schizophrenia: a review and reconceptualization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Dopamine receptor pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D(2) binding ratios on SPECT imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia--findings from an in vivo SPECT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Dopaminergic dysfunction in alcoholism and schizophrenia--psychopathological and behavioral correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

'Jumping to conclusions' and delusions in psychosis: relationship and response to treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

The principal features and mechanisms of dopamine modulation in the prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Do patients with schizophrenia exhibit aberrant salience?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

A review of reward processing and motivational impairment in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Decreased 5-HT1A receptor binding in amygdala of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Serotonin 1A receptor availability in patients with schizophrenia and schizo-affective disorder: a positron emission tomography imaging study with [11C]WAY 100635.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Role of dopamine in the behavioural actions of nicotine related to addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Nicotine-induced dopamine release in primates measured with [11C]raclopride PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Nicotine Fails to Attenuate Ketamine-Induced Cognitive Deficits and Negative and Positive Symptoms in Humans: Implications for Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Nicotinic acetylcholine receptor expression on B-lymphoblasts of healthy versus schizophrenic subjects stratified for smoking: [3H]-nicotine binding is decreased in schizophrenia and correlates with negative symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Correlation of prepulse inhibition and Wisconsin Card Sorting Test in schizophrenia and controls: effects of smoking status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Prepulse inhibition deficits in schizophrenia are modified by smoking status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Why do patients with schizophrenia smoke?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Differential regulation of alpha7 nicotinic receptor gene (CHRNA7) expression in schizophrenic smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Initial phase 2 trial of a nicotinic agonist in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Glutamate as a therapeutic target in psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Neuronal calcium-binding proteins and schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Recent advances in the phencyclidine model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Schizophrenia: diverse approaches to a complex disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Capturing the Angel in "Angel Dust": Twenty Years of Translational Neuroscience Studies of NMDA Receptor Antagonists in Animals and Humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

From Revolution to Evolution: The Glutamate Hypothesis of Schizophrenia and its Implication for Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Glutamate neurocircuitry: theoretical underpinnings in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

In vivo measurements of glutamate, GABA, and NAAG in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Proton magnetic resonance spectroscopy of the substantia nigra in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Double-blind, placebo-controlled, crossover trial of clozapine plus glycine in refractory schizophrenia negative results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Group II mGluR agonist LY354740 and NAAG peptidase inhibitor effects on prepulse inhibition in PCP and D-amphetamine models of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

DOI-induced deficits in prepulse inhibition in Wistar rats are reversed by mGlu2/3 receptor stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Sensorimotor gating, working and social memory deficits in mice with reduced expression of the vesicular glutamate transporter VGLUT1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Deficient prepulse inhibition in schizophrenia detected by the multi-site COGS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

The T393C polymorphism of the GNAS1 gene is associated with deficit schizophrenia in an Italian population sample.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Lack of association between COMT gene and deficit/nondeficit schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

The PIP5K2A and RGS4 genes are differentially associated with deficit and non-deficit schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Mixture model clustering of phenotype features reveals evidence for association of DTNBP1 to a specific subtype of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

BDNF rs 6265 polymorphism and COMT rs 4680 polymorphism in deficit schizophrenia in Polish sample.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Dysbindin genotype and negative symptoms in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Sensorimotor gating is associated with CHRNA3 polymorphisms in schizophrenia and healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: Ser311Cys polymorphisms of the dopamine D2-receptor gene and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Catechol-O-methyltransferase Val158Met polymorphism and clinical characteristics in first episode non-affective psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Analysis of association between the catechol-O-methyltransferase (COMT) gene and negative symptoms in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Catechol-O-methyltransferase and the clinical features of psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Association of Catechol‐O‐methyltransferase gene polymorphisms with schizophrenia and negative symptoms in a Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Association of MB-COMT polymorphisms with schizophrenia-susceptibility and symptom severity in an African cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Preliminary structure and predictive value of attenuated negative symptoms in 22q11.2 deletion syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Association between catechol-O-methyltransferase Val158Met polymorphism and negative symptoms of schizophrenia in the Korean population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Anhedonia as a phenotype for the Val158Met COMT polymorphism in relatives of patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Association of variants in DISC1 with psychosis-related traits in a large population cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Catechol-O-methyltransferase Val158Met polymorphism in schizophrenia: associations with cognitive and motor impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

COMT Val(158)Met and BDNF C(270)T polymorphisms in schizophrenia: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Inferior frontal white matter anisotropy and negative symptoms of schizophrenia: a diffusion tensor imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Clinical and neuropsychological correlates of white matter abnormalities in recent onset schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Structural correlates of psychopathological symptom dimensions in schizophrenia: A voxel-based morphometric study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Schizotypal dimensions: An intermediate phenotype associated with the COMT high activity allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00406-015-0590-4

Computed Tomographic Evidence for Generalized Sulcal and Ventricular Enlargement in Schizophrenia

21 January 2018

1 reference

12 December 2020

Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex

1 reference

12 December 2020

Association between the SLC6A12 gene and negative symptoms of schizophrenia in a Korean population

1 reference

12 December 2020

Regional cerebral blood flow and negative/positive symptoms in 24 drug-naive schizophrenics

1 reference

12 December 2020

Deficit schizophrenia: an update

1 reference

12 December 2020

Cortical-striatal-thalamic circuits and brain glucose metabolic activity in 70 unmedicated male schizophrenic patients

1 reference

12 December 2020

Volumetric measure of the frontal and temporal lobe regions in schizophrenia: relationship to negative symptoms

1 reference

12 December 2020

Novel alpha7 nicotinic receptor isoforms and deficient cholinergic transcription in schizophrenia

1 reference

12 December 2020

Prefrontal dopamine D1 receptors and working memory in schizophrenia.

1 reference

12 December 2020

Beyond the dopamine hypothesis to the NMDA glutamate receptor hypofunction hypothesis of schizophrenia.

1 reference

12 December 2020

Frontal and temporal lobe brain volumes in schizophrenia. Relationship to symptoms and clinical subtype

1 reference

12 December 2020

Plasma 3-methoxy-4-hydroxyphenylglycol and homovanillic acid measurements in deficit and nondeficit forms of schizophrenia

1 reference

12 December 2020

Catechol-O-methyltransferase Val158Met polymorphism and negative symptoms after acute antipsychotic treatment in first-episode non-affective psychosis

1 reference

12 December 2020

Clinical, biological, and neuropsychological features associated with lateral ventricular enlargement in DSM-III schizophrenic disorder

1 reference

12 December 2020

High-resolution SPECT study of regional cerebral blood flow in drug-free and drug-naive schizophrenic patients

1 reference

12 December 2020

[The dopamine hypothesis of schizophrenia. New findings for an old theory]

1 reference

12 December 2020

Is avolition in schizophrenia associated with a deficit of dorsal caudate activity? A functional magnetic resonance imaging study during reward anticipation and feedback

1 reference

12 December 2020

Morphology of the lateral superior temporal gyrus in neuroleptic nai;ve patients with schizophrenia: relationship to symptoms.

1 reference

12 December 2020

The neural basis of the deficit syndrome of schizophrenia

1 reference

12 December 2020

A comparison of plasma homovanillic acid in the deficit and nondeficit subtypes of schizophrenia

1 reference

12 December 2020

Schizophrenic patients with deficit syndrome have higher plasma homovanillic acid concentrations and ventricular enlargement

1 reference

12 December 2020

Mazindol treatment of negative symptoms

1 reference

12 December 2020

Anhedonia and the experience of emotion in individuals with schizophrenia

1 reference

12 December 2020

Gray matter changes in patients with deficit schizophrenia and non-deficit schizophrenia.

1 reference

12 December 2020

Impaired prepulse inhibition of acoustic startle in Chinese patients with first-episode, medication-naïve schizophrenia.

1 reference

12 December 2020

Positive and Negative Symptom Response to Clozapine in Schizophrenic Patients With and Without the Deficit Syndrome

1 reference

12 December 2020

Deficit and nondeficit forms of schizophrenia: the concept

1 reference

12 December 2020

Influence of DRD2 polymorphisms on the clinical outcomes of patients with schizophrenia

1 reference

12 December 2020

Association study of catechol-O-methyltransferase gene polymorphisms with schizophrenia and psychopathological symptoms in Han Chinese

1 reference

12 December 2020

Lateral ventricular size, psychopathology, and medication response in the psychoses

1 reference

12 December 2020

Nicotine dependence and schizophrenia

1 reference

12 December 2020

Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia.

1 reference

12 December 2020

Relationship between a high-risk haplotype in the DTNBP1 (dysbindin) gene and clinical features of schizophrenia

1 reference

12 December 2020

Impaired sensorimotor gating in schizophrenia with deficit and with nondeficit syndrome.

1 reference

12 December 2020

Amphetamines for schizophrenia

1 reference

12 December 2020

Dopaminergic Neurotransmission in Patients with Schizophrenia in Relation to Positive and Negative Symptoms

1 reference

12 December 2020

Neural mechanisms of negative symptoms

1 reference

12 December 2020

10.1007/S00406-015-0590-4

Identifiers

DOI

1 reference

Dimensions Publication ID

27 June 2017

1000758535

0 references

1 reference